Boundless Bio, Inc. (BOLD) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the S-4 for Q2 FY2026, filed Oct 8, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BOLD SEC filings page.
This page shows Boundless Bio, Inc. (BOLD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Boundless Bio operates as a research-led business, consuming capital before revenue generation appears in the reported statements.
From FY2024 to FY2025, the net loss narrowed to$58.2M and operating cash outflow fell to$46.7M , yet total assets declined by roughly$49.4M as financing inflow nearly disappeared. That combination suggests lower spending reduced cash consumption, but the balance sheet was not replenished by new capital during the year.
The reported expense mix remains centered on research and development: FY2025 R&D was
The balance sheet shifted from negative equity in FY2023 to
Financial Health Signals
Boundless Bio, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Boundless Bio, Inc. passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Boundless Bio, Inc. reported a net loss of $58.2M while operations used $46.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Boundless Bio, Inc.'s EBITDA was -$23.1M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 37.7% from the same quarter a year earlier. Against the prior quarter it is down 62.7%.
Boundless Bio, Inc. reported -$23.7M in net income in Q2 2026. This represents a decrease of 51.2% from the same quarter a year earlier. Against the prior quarter it is down 74.8%.
Boundless Bio, Inc. earned -$1.06 per diluted share (EPS) in Q2 2026. This represents a decrease of 51.4% from the same quarter a year earlier. Against the prior quarter it is down 76.7%.
Not reported for Q2 2026.
Cash & Balance Sheet
Boundless Bio, Inc. recorded an outflow of $21.0M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 76.9% from the same quarter a year earlier. Against the prior quarter it is down 40.3%.
Boundless Bio, Inc. held $20.2M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Boundless Bio, Inc.'s ROE was -35.9% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 23.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 20.2 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Boundless Bio, Inc. invested $14.0M in research and development in Q2 2026. This represents an increase of 14.4% from the same quarter a year earlier. Against the prior quarter it is up 43.5%.
Boundless Bio, Inc. invested $38K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 20.8% from the same quarter a year earlier. Against the prior quarter it is up 375.0%.
Not reported for Q2 2026.
BOLD Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'26S-4 | Q1'26S-4 | Q4'25S-4 | Q3'2510-Q | Q2'25S-4 | Q1'25S-4 | Q4'24S-4 | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $14.0M+14.4% | $9.7M-19.8% | N/A | $10.7M-24.2% | $12.2M-17.1% | $12.1M-7.5% | N/A | $14.1M+21.0% |
| SG&A Expenses | $10.4M+115.0% | $4.7M-8.9% | N/A | $4.5M-3.3% | $4.8M+4.0% | $5.2M+38.6% | N/A | $4.6M+39.8% |
| Operating Income | -$24.4M-42.9% | -$14.5M+16.5% | N/A | -$15.1M+19.1% | -$17.1M+12.0% | -$17.3M-2.7% | N/A | -$18.7M-25.2% |
| EBITDA | -$23.1M-37.7% | -$14.2M+16.6% | N/A | -$14.8M+19.4% | -$16.8M+12.2% | -$17.0M-2.4% | N/A | -$18.4M-24.8% |
| Net Income | -$23.7M-51.2% | -$13.6M+14.0% | N/A | -$13.9M+15.9% | -$15.7M+7.7% | -$15.8M-2.1% | N/A | -$16.5M-25.3% |
| EPS (Basic) | -$1.06-51.4% | -$0.60+15.5% | -$0.57+9.5% | -$0.62+16.2% | -$0.70+9.1% | -$0.71+94.2% | -$0.63+93.5% | -$0.74+93.1% |
| EPS (Diluted) | -$1.06-51.4% | -$0.60+15.5% | -$0.57+9.5% | -$0.62+16.2% | -$0.70+9.1% | -$0.71 | -$0.63 | -$0.74 |
| Diluted Shares (Avg) | 22M+0.4% | 22M+0.5% | N/A | 22M+0.6% | 22M+1.5% | 22M | N/A | 22M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.
BOLD Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'26S-4 | Q1'26S-4 | Q4'25S-4 | Q3'2510-Q | Q2'25S-4 | Q1'25S-4 | Q4'24S-4 | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $73.7M-58.9% | $141.0M-26.3% | $157.1M-23.9% | $168.7M-3.6% | $179.5M-4.6% | $191.2M+63.3% | $206.4M+58.9% | $175.1M |
| Current Assets | $73.6M-43.2% | $94.6M-32.6% | $109.6M-29.0% | $120.2M-29.5% | $129.7M-29.2% | $140.4M+25.1% | $154.4M+24.3% | $170.4M |
| Cash & Equivalents | $20.2M+37.5% | $17.5M+15.7% | $17.9M-32.8% | $15.0M-62.7% | $14.7M-53.1% | $15.1M-39.9% | $26.6M+12.2% | $40.2M+91.8% |
| Short-Term Investments | $52.4M-53.4% | $75.4M-38.8% | $89.7M-28.5% | $102.6M-19.2% | $112.5M-24.0% | $123.1M+54.4% | $125.5M+29.3% | $126.9M |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $7.8M-86.3% | $54.6M-0.1% | $58.4M+4.7% | $58.6M+484.9% | $56.8M+533.7% | $54.6M-78.8% | $55.8M-78.3% | $10.0M |
| Current Liabilities | $7.8M-15.7% | $9.6M+51.2% | $12.5M+54.1% | $11.8M+18.3% | $9.2M+2.9% | $6.3M-40.5% | $8.1M-13.1% | $10.0M |
| Non-Current Liabilities | $0-100.0% | $45.0M-6.8% | $45.9M-3.7% | $46.7M | $47.5M | $48.3M-80.5% | $47.6M-80.8% | $0 |
| Total Equity | $66.0M-46.2% | $86.4M-36.8% | $98.7M-34.5% | $110.2M-33.3% | $122.7M-31.6% | $136.6M+196.7% | $150.6M+218.5% | $165.1M+242.3% |
| Retained Earnings | -$296.9M-27.5% | -$273.2M-25.8% | -$259.7M-28.9% | -$246.8M-33.4% | -$232.9M-38.2% | -$217.2M-43.3% | -$201.5M-48.0% | -$185.0M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
BOLD Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'26S-4 | Q1'26S-4 | Q4'25S-4 | Q3'2510-Q | Q2'25S-4 | Q1'25S-4 | Q4'24S-4 | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$21.0M-77.3% | -$15.0M-3.0% | -$10.1M+35.1% | -$10.2M+23.1% | -$11.8M+27.1% | -$14.5M+7.9% | -$15.6M-33.2% | -$13.3M-8.8% |
| Depreciation & Amortization | $1.3M+333.3% | $284K-10.4% | $307K+3.7% | $300K0.0% | $300K0.0% | $317K+20.5% | $296K+19.8% | $300K+50.0% |
| Stock-Based Compensation | $3.2M+90.3% | $1.4M-23.7% | N/A | $1.3M-36.3% | $1.7M-20.7% | $1.8M+35.3% | N/A | $2.0M+131.6% |
| Capital Expenditures | $38K-20.8% | $8K-86.4% | $424K-9.0% | $15K-96.9% | $48K-96.8% | $59K-28.9% | $466K+73.9% | $483K+219.9% |
| Free Cash Flow | -$21.0M-76.9% | -$15.0M-2.7% | -$10.5M+34.3% | -$10.2M+25.7% | -$11.9M+33.0% | -$14.6M+8.0% | -$16.0M-34.1% | -$13.7M-11.4% |
| Investing Cash Flow | $23.1M+104.3% | $14.6M+376.7% | $13.0M+611.5% | $10.5M-52.7% | $11.3M+116.6% | $3.1M-83.1% | $1.8M-88.5% | $22.1M+386.8% |
| Financing Cash Flow | N/A | N/A | $24K-78.8% | $0+100.0% | N/A | N/A | $113K+108.2% | -$13K+97.1% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
BOLD Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'26S-4 | Q1'26S-4 | Q4'25S-4 | Q3'2510-Q | Q2'25S-4 | Q1'25S-4 | Q4'24S-4 | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -35.9%-23.1pp | -15.7%-4.2pp | N/A | -12.6%-2.6pp | -12.8%-3.3pp | -11.5% | N/A | -10.0% |
| Return on Assets | -32.1%-23.4pp | -9.6%-1.4pp | N/A | -8.2%+1.2pp | -8.7%+0.3pp | -8.2%+4.9pp | N/A | -9.4% |
| Current Ratio | 9.48-4.6x | 9.87-12.3x | 8.74-10.2x | 10.14-6.9x | 14.08-6.4x | 22.15+11.6x | 18.98+5.7x | 17.03 |
| Debt-to-Equity | 0.12-0.3x | 0.63+0.2x | 0.59+0.2x | 0.53+0.5x | 0.46+0.4x | 0.40 | 0.37 | 0.06 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Boundless Bio, Inc. BOLD | FY2025 | N/A | -$58.2M | N/A | $58.5M | — |
| Allarity Therapeutics, Inc. ALLR | FY2025 | $320K | -$11.2M | N/A | $15.7M | — |
| Neuphoria Therapeutics Inc. NEUP | FY2026 | $1.2M | -$13.5M | N/A | $18.1M | 48/100 |
| Rein Therapeutics, Inc. RNTX | FY2025 | $0 | -$49.9M | N/A | $66.4M | — |
| Akari Therapeutics plc AKTX | FY2025 | N/A | -$17.3M | N/A | $18.6M | — |
| Lixte Biotechnology Holdings, Inc. LIXT | FY2025 | N/A | -$6.1M | N/A | $125.4M | — |
Where Boundless Bio, Inc. Ranks
Frequently Asked Questions
Is Boundless Bio, Inc. profitable?
No, Boundless Bio, Inc. (BOLD) reported a net income of -$58.2M in fiscal year 2025.
What is Boundless Bio, Inc.'s EBITDA?
Boundless Bio, Inc. (BOLD) had EBITDA of -$62.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Boundless Bio, Inc.'s return on equity (ROE)?
Boundless Bio, Inc. (BOLD) has a return on equity of -59.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Boundless Bio, Inc.'s free cash flow?
Boundless Bio, Inc. (BOLD) recorded an outflow of $47.2M in free cash flow during fiscal year 2025. This represents a 25.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Boundless Bio, Inc.'s operating cash flow?
Boundless Bio, Inc. (BOLD) recorded an outflow of $46.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Boundless Bio, Inc.'s total assets?
Boundless Bio, Inc. (BOLD) had $157.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Boundless Bio, Inc.'s capital expenditures?
Boundless Bio, Inc. (BOLD) invested $546K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Boundless Bio, Inc. spend on research and development?
Boundless Bio, Inc. (BOLD) invested $44.8M in research and development during fiscal year 2025.
What is Boundless Bio, Inc.'s current ratio?
Boundless Bio, Inc. (BOLD) had a current ratio of 8.74 as of fiscal year 2025, which is generally considered healthy.
What is Boundless Bio, Inc.'s debt-to-equity ratio?
Boundless Bio, Inc. (BOLD) had a debt-to-equity ratio of 0.59 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Boundless Bio, Inc.'s return on assets (ROA)?
Boundless Bio, Inc. (BOLD) had a return on assets of -37.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Boundless Bio, Inc.'s P/E ratio?
Boundless Bio, Inc. (BOLD) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $58.5M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Boundless Bio, Inc.'s price-to-sales ratio?
Boundless Bio, Inc. (BOLD) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $58.5M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Boundless Bio, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Boundless Bio, Inc. (BOLD) held $107.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $46.7M over that year. Dividing the one by the other, the reported balance equals about 28 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Boundless Bio, Inc.'s Piotroski F-Score?
Boundless Bio, Inc. (BOLD) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Boundless Bio, Inc.'s earnings high quality?
Boundless Bio, Inc. (BOLD) reported a net loss of $58.2M while operations used $46.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.